The Medical Advisor

Abstract Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially developed for type 2 diabetes, have rapidly expanded into obesity management and are now being explored across multiple therapeutic domains. Recent studies (2024–2026) suggest potential benefits in dermatologic diseases, neuroinflammatory conditions, metabolic dysfunction, and systemic inflammation. In parallel, emerging clinical guidance highlights the importance of nutritional status, targeted supplementation, and safety considerations—including concerns around compounded formulations. This review synthesizes current evidence and practical considerations for optimizing outcomes. 1. Introduction GLP-1 receptor agonists—including semaglutide, liraglutide, and tirzepatide—have transformed the management of obesity and type 2 diabetes. Their mechanisms extend beyond glucose regulation to include: Appetite suppression Delayed gastric emptying Anti-inflammatory effects Modulation of insulin sensitivity As clinical us...

Weight-loss medications such as Ozempic, Wegovy, Mounjaro, and Zepbound have reshaped obesity treatment. By 2026, millions of people are using GLP-1 receptor agonists or dual GLP-1/GIP drugs to lose weight, improve metabolic health, and reduce cardiometabolic risk. But there’s a hidden issue clinicians are increasingly discussing: Up to 30–40% of the weight lost on GLP-1 therapy can come from lean muscle mass. If that muscle loss isn’t addressed, patients may reach their goal weight but end up with slower metabolism, reduced strength, and higher long-term weight regain risk. This is sometimes called “GLP-1 muscle drain.” The solution isn’t stopping the medication. Instead, experts are increasingly recommending a Protein-Sparing Protocol —a structured approach designed to preserve muscle while maximizing fat loss. Below is the practical, evidence-informed roadmap. 1. The Problem: The “Muscle Drain” Phenomenon GLP-1 medications work primarily by: Slowing gastric emptying Increasing satie...

Introduction In an era where conventional cancer treatments often come with significant side effects and variable success rates, alternative therapies are gaining attention for their potential accessibility and lower toxicity. This exploration delves into the emerging use of topical ivermectin—a well-established antiparasitic medication—for treating skin cancers such as basal cell carcinoma, squamous cell carcinoma, and melanoma. Drawing from a compilation of anecdotal success stories, case reports, and preliminary scientific insights, we examine how this affordable, over-the-counter option might disrupt traditional dermatological approaches. While not a substitute for professional medical advice, these narratives highlight patient-driven innovations that challenge the status quo, prompting a closer look at ivermectin's multifaceted mechanisms and real-world applications. Case Presentations Case 16 - 2026: 66 year old Texas nurse with Basal Cell Carcinoma at the nose/cheek jun...